Bismuth Quadruple Therapy for H. pylori Infection
Bismuth quadruple therapy consists of four medications taken together: a proton pump inhibitor (PPI), bismuth subsalicylate or bismuth subcitrate, tetracycline 500 mg, and metronidazole 500 mg, administered for 14 days. This regimen is one of only two therapies that can be given empirically without susceptibility testing and remains highly effective even against antibiotic-resistant strains 1.
Standard Regimen Components and Dosing
The classic bismuth quadruple therapy includes 1:
- Bismuth subsalicylate (e.g., Pepto-Bismol®): 2 tablets or capsules four times daily, taken 30 minutes before meals
- Tetracycline HCl: 500 mg four times daily, taken 30 minutes after meals
- Metronidazole: 500 mg four times daily (or three times daily in some protocols), taken 30 minutes after meals
- PPI: Twice daily, 30 minutes before meals and at bedtime
- Duration: 14 days for optimal efficacy
Alternative Dosing Schedule
A simplified regimen uses 1:
- Bismuth: 2 tablets/capsules four times daily before meals
- Tetracycline: 500 mg twice daily after meals
- Metronidazole: 500 mg four times daily after meals
- PPI: Twice daily before morning and evening meals
PPI Selection and Dosing
The choice of PPI significantly impacts treatment success—use high-potency PPIs and avoid pantoprazole 1. Recommended options include:
- Esomeprazole or rabeprazole 20-40 mg twice daily (preferred)
- Omeprazole 40 mg twice daily minimum
- Lansoprazole 45 mg twice daily
- Avoid pantoprazole due to lower potency (40 mg pantoprazole = only 9 mg omeprazole equivalent)
Formulation Options
Three-in-One Capsule (Pylera®)
A combination capsule containing bismuth subcitrate, metronidazole, and tetracycline is available, taken as 3 capsules four times daily with meals plus a PPI 1, 2. This formulation:
- Simplifies administration and improves adherence
- Achieves >90% eradication rates in real-world practice
- Is packaged for 10 days but 14-day therapy is preferred for optimal results
- Costs vary significantly: ~€70 in Europe vs >$900-1000 in the United States
Generic Components
All medications can be prescribed separately, which may be more cost-effective in some regions 1. Generic tetracycline costs ~$660 retail in the US but can be obtained for <$100 with discount coupons.
Clinical Efficacy
Bismuth quadruple therapy maintains eradication rates >90% as first-line therapy and remains highly effective as rescue therapy 2, 3:
- First-line treatment: 95% modified intention-to-treat (mITT) eradication 2
- Second-line rescue: 89% mITT eradication 2
- Third-line and beyond: 92% mITT eradication 2
- Against multidrug-resistant strains: 87% per-protocol eradication even with dual or triple antibiotic resistance 4
The regimen's effectiveness persists through multiple treatment lines, though cure rates drop below 67% after four or more failed attempts 4.
Treatment Duration
Fourteen-day therapy is recommended over 10-day regimens 1, 3. While 10-day courses show comparable eradication rates in some studies 5, the most recent guidelines emphasize 14 days for optimal outcomes, particularly in first-line therapy 1.
Important Caveats and Pitfalls
Tetracycline Substitution
Do not substitute doxycycline for tetracycline—results are significantly inferior 1. Minocycline may serve as an alternative when tetracycline is unavailable, but this is not standard practice 3.
Compliance
Patient adherence is the single most important factor predicting treatment success 2, 6. The three-in-one capsule formulation improves compliance compared to separate medications.
Resistance Patterns
Bismuth quadruple therapy maintains high efficacy regardless of clarithromycin, metronidazole, or levofloxacin resistance 4, 3. This makes it ideal for empiric therapy when local resistance rates are unknown or high.
Clinical Indications
Bismuth quadruple therapy is recommended as 7, 1:
- First-line therapy in regions where clarithromycin resistance exceeds 15%
- Rescue therapy after failure of clarithromycin-based triple therapy
- Rescue therapy after failure of fluoroquinolone-based regimens
- First choice for patients with penicillin allergy
Safety Profile
The regimen is generally well-tolerated 2, 3:
- Adverse events occur in 16-23% of patients
- Most side effects are mild to moderate gastrointestinal symptoms
- Black/discolored stools are common but benign
- Severe adverse events leading to discontinuation occur in only 1.7-3% of cases
- Diarrhea is more common than with other regimens
Dosing Optimization
Standard antibiotic and bismuth doses are sufficient—higher doses do not improve eradication rates 8. The optimal regimen uses:
- Tetracycline ≥1500 mg/day
- Metronidazole 1500 mg/day
- Bismuth ≥480 mg/day
Increasing doses beyond these thresholds provides no additional benefit and may increase adverse events 8.